Christopher Bunker

Company: Alamar Biosciences Inc.

Job title: Vice President - Biopharma Business Development

Seminars:

NULISA: Ultra-Sensitive & Multiplex Immunoassay Platform for Fluid-Based Neurodegenerative Biomarker Detection 9:00 am

New biomarker assay technology, NULISA™ – with ultra-sensitive femtogram level detection with proprietary background suppression technology Unique NULISA CNS Disease Panel detecting nearly 120 critical biomarkers covering Alzheimer’s and Parkinson's Disease as well as other CNS-related diseases Ultra-sensitive NULISA technology holds great promise to enable early detection and monitoring of neurodegenerative diseases to aid in…Read more

day: Conference Day Two